Adoptive Cell Transfer

The FDA granted fast track designation to TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme, according to the agent’s manufacturer.

Evaluation by a multidisciplinary team clinic prior to hematopoietic stem cell transplantation appeared to reduce transplant-related morbidity and mortality among older adults with blood cancers, according to results of a prospective survey-based study published in Blood Advances.

Cervical Cancer Awareness Month is observed every January.

NATIONAL HARBOR, Md. — Certain genetic biomarkers predicted long-term overall survival for patients who received adoptive cell therapy with tumor infiltrating lymphocytes for metastatic melanoma, according to the results of a multicenter, retrospective study presented at Society for Immunotherapy of Cancer Annual Meeting.

Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.

Immatics Biotechnologies, a Germany-based biopharma company, has entered into a strategic agreement with Celgene on the development of new adoptive cell therapies for the treatment of cancer, according to a company press release.

Editor’s note: This is the first in a series of articles that spotlight research efforts supported through Cancer Research Institute’s Lloyd J. Old STAR program. The program provides up to $1.25 million over a 5-year period to mid-career scientists who pursue high-risk, high-reward research in cancer immunotherapy.

Biotech firm Phio Pharmaceuticals announced it has entered into a research collaboration with Helmholtz Zentrum München, the German Research Center for Environmental Health, to develop T cell and natural killer cell adoptive cell therapies for the treatment of solid tumors.